|
Program Goals
The 11th annual PANAO will focus on the large number of new anticancer agents and related supportive therapeutics that have been approved over the last several years, as well as those that will likely be approved. Speakers will discuss the incorporation of these agents into standard clinical practice, providing guidance to front-line clinicians, nurses and pharmacist regarding current or projected appropriate use of these therapeutics.
Target Audience
There is a necessity to continually update the community of medical professionals within the field of oncology with new agents and their uses in the clinical setting. A need also exits to foster collaboration between physicians, pharmacists and nurses treating cancer patients. This conference offers an opportunity to gather these professionals to one arena to learn about and discuss new agents in oncology and their uses in the clinical setting.
The conference has an attractive format and represents national points of view, making it a stimulating meeting for primary care and oncology clinicians, physicians, nurses, nurse practitioners, physician assistants, other allied health professionals, and students.
Educational Objectives
Objectives are statements that clearly describe what the learner will be able to know or do after participating in the CME activity.
- Cite the results of clinical studies of new anticancer agents and current dilemmas with a principal focus on discerning the role or eventual role of new therapies in the clinical practice of oncology.
- Describe the procedure for determining incorporation of new anticancer agents and therapeutics into clinical practice.
- Discuss management of adverse effects associated with cancer treatment
- Choose appropriate treatment options for patients with cancer based on clinical data and individual patient characteristics
- Discuss novel agents in development for the treatment of cancer
- Outline the biological principles of angiogenesis inhibition in metastatic renal cell carcinoma
- Discuss management of adverse effects associated with cancer treatment
- Discuss the incidence, epidemiology, molecular biology, and survival of patients with NSCLC
- List the active novel targeted agents and newer combinations currently being investigated in NSCLC
- Hear about the future directions utilizing the newer non-cytotoxic agents in the treatment of NSCLC, including the use of novel agents, regimens, and dosing techniques.
- Describe nursing interventions for potential cardiac and dermatologic toxicities associated with oncology targeted therapies.
- Name the three most significant nursing interventions in administering a first-in-man oncology targeted therapy.
- Identify learning resources for patients who are undergoing treatment with new oncology therapies
- Explain how the clinical trials nurse is essential to human research protections in testing new agents.
- Improve knowledge of Institutional Review Board (IRB) requirements and how to work with your IRB to mutual benefit.
Educational Methods
The course will include lectures and opportunity for questions and answers.
Accreditation
Continuing Medical Education Statements
The UT Health Science Center San Antonio School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
UT Health Science Center San Antonio School of Medicine designates this educational activity for a maximum of 8.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Statements
The University of Texas Health Science Center at San Antonio, School of Nursing, is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity meets Type I criteria for mandatory continuing education requirements toward relicensure as established by the Texas Board of Nursing. This education program offers up to 9.9 nursing contact hours.
Continuing Pharmacy Education Statements
 The University of Texas College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists who successfully complete this program will receive 0.7 CEUs (7 contact hours) of continuing education credit. Successful completion of the program is defined as attending the entire conference and
completing a Record of Attendance/Evaluation Form. Continuing education
statements will be mailed by The University of Texas directly to participants
within 6-8 weeks following the program.
Program No. 067-999-09-005-L01-P
Conference Contact
Rich Markow, Symposia Director
UT Health Science Center San Antonio
Continuing Medical Education
7703 Floyd Curl Drive, MC8224
San Antonio, TX 78229-3900
Tel (210) 567-6070
Fax (210) 567-6072
E-mail markow@uthscsa.edu
Conference Administration
All administrative functions of this conference occur in the Symposium operations office at the address above.
Program Committee
Tyler Curiel, MD, MPH
Course Co-Director
Executive Director
Cancer Therapy & Research Center at UT Health Science Center San Antonio
Monica Mita, MD
Course Co-Director
Clinical Investigator
Assistant Professor of Medicine
Cancer Therapy & Research Center at UT Health Science Center San Antonio
Institute for Drug Development
Andrew Brenner, MD, PhD
Assistant Professor, Hematology and Medical Oncology
Cancer Therapy & Research Center at UT Health Science Center San Antonio
Jennifer Carew, PhD
Assistant Professor, Hematology and Medical Oncology
Cancer Therapy & Research Center at UT Health Science Center San Antonio
Brenda Johnson MEd
Director, Continuing Medical Educatio
UT Health Science Center San Antonio
Anand Karnad, MD
Professor, Hematology and Medical Oncology, Castella Aging Chair
Cancer Therapy & Research Center at UT Health Science Center San Antonio
Gerardo Medina, RN, OCN, CCRP
Research Nursing Supervisor
Cancer Therapy & Research Center at UT Health Science Center San Antonio
Institute for Drug Development
Rosalie Tierney-Gumaer, BSN, MSN, MOH, CPHQ
Director, Continuing Nursing Education
UT Health Science Center San Antonio
Gail Tomlinson, MD, PhD
Professor, Pediatrics
Greehey Distinguished Chair in Genetics of Cance
UT Health Science Center San Antonio
|
Home
Practical Applications of New Agents in Oncology
